Previous Close | 0.582 |
1-Year Change | -84.84% |
6-Months Change | -55.57% |
3-Months Change | -72.42% |
Moving Avg (50d) | 1.2444 |
Moving Avg (200d) | 1.8654 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 70.2M |
Beta (3-Years) | 1.62 |
Revenue Growth (ttm) | 243.09% |
Net Profit Margin (ttm) | -482.47% |
Return On Assets (ttm) | -74.95% |
EPS (ttm) | -1.77 |
PE Ratio (ttm) | -0.33 |
Dividend Yield | % |
Asset Description: | Mersana Therapeutics, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-12-12 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
0.594 | 0.611 | 0.623 | 0.64 | 0.669 | 0.698 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |